With growing interest in obesity treatments, Goldman Sachs just raised its market estimates from $100 billion to $130 billion.
“The estimate was revised as the firm projects the number of Americans on anti-obesity drugs could reach ~19M by 2030, up from its previous estimate of ~15M. This indicates a ~17% market penetration among U.S. adults,” as noted by Seeking Alpha.
|
While that’s certainly great news for obesity treatment heavyweights like Eli Lilly (SYM: LLY) and Novo Nordisk (SYM: NVO), it’s also fueling momentum in up-and-coming treatment stocks, like: Company: Altimmune (SYM: ALT) Company: Structure Therapeutics (SYM: GPCR) GPCR is moving forward with its 36-week Phase 2b obesity study later this year. GPCR believes its GSBR-1290 obesity treatment is “uniquely positioned as an oral, non-peptide small molecule GLP-1 receptor agonist that can be manufactured at scale and significantly help address the growing obesity epidemic, which current peptide GLP-1s are not able to do.” Monument Traders Alliance JOLTS OVERNIGHT TRADE DEMONSTRATION Found this helpful? Share it with others. Written by Dylan Jovine |
